Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis

Journal of Biological Chemistry

Volumn 289, Issue 42, 2014, Pages 29014-29029

  Harari, Daniel ^a   Kuhn, Nadine ^a   Abramovich, Renne ^a   Sasson, Keren ^a   Zozulya, Alla L ^a,f   Smith, Paul ^a,g   Schlapschy, Martin ^a   Aharoni, Rina ^b   Köster, Mario ^c   Eilam, Raya ^d   Skerra, Arne ^a,e   Schreiber, Gideon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c XL Protein GmbH   (Germany)

^d MERCK SERONO S A   (Switzerland)

^e HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^f Novartis Pharma Schweiz AG   (Switzerland)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBIOTICS; BIOCHEMISTRY; DISEASE CONTROL; MAMMALS;

BIOLOGICAL POTENCY; BIOLOGICAL PROPERTIES; CLINICAL RESPONSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOHISTOCHEMISTRY; MULTIPLE SCLEROSIS; POLYPEPTIDE CHAIN; TYPE I INTERFERONS;

GLYCOPROTEINS;

ALLOGRAFT INFLAMMATORY FACTOR 1; ALPHA BETA INTERFERON RECEPTOR; ALPHA2 INTERFERON; BETA INTERFERON; CD11B ANTIGEN; CD45 ANTIGEN; HUMAN INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERFERON SUPERAGONIST YNS; INTERFERON SUPERAGONIST YNS ALPHA 8; NEUROPROTECTIVE AGENT; PASYLATED INTERFERON SUPERAGONIST YNS ALPHA 8; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG; INTERFERON; PAS-YNSALPHA8 PEPTIDE; PEPTIDE; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CACHEXIA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SYNTHESIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; IRF7 GENE; LOW DRUG DOSE; MOUSE; MULTIPLE SCLEROSIS; MX1 GENE; NEUROPROTECTION; NONHUMAN; PASYLATION TECHNOLOGY; PROTEIN ENGINEERING; PROTEIN MODIFICATION; TRANSGENIC MOUSE; TREATMENT DURATION; UPREGULATION; USP18 GENE; AGONISTS; ANIMAL; C57BL MOUSE; CELL SEPARATION; CHEMISTRY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; METABOLISM; PROCEDURES; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME;

ANIMALS; CELL SEPARATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; PEPTIDES; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME;

EID: 84908046817     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.602474     Document Type: Article

References (59)

1. Goverman, J. (2009) Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9, 393-407
2. Ebers, G. C. (2008) Environmental factors and multiple sclerosis. Lancet Neurol. 7, 268-277
3. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 476, 214-219
4. International Multiple Sclerosis Genetics Consortium (IMSGC) (2013) Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 45, 1353-1360
5. McFarland, H. F., and Martin, R. (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8, 913-919
6. IFNB Multiple Sclerosis Study Group (1993) Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43, 655-661
7. Schwid, S. R., and Panitch, H. S. (2007) Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis. Clin. Ther. 29, 2031-2048
8. Mahurkar, S., Suppiah, V., and O'Doherty, C. (2014) Pharmacogenomics of interferon β and glatiramer acetate response: a review of the literature. Autoimmun. Rev. 13, 178-186
9. Pestka, S., Krause, C. D., and Walter, M. R. (2004) Interferons, interferonlike cytokines, and their receptors. Immunol. Rev. 202, 8-32
10. Platanias, L. C. (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386
11. Borden, E. C, Sen, G. C, Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., and Stark, G. R. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6, 975-990
12. Uzé, G., Schreiber, G., Piehler, J., and Pellegrini, S. (2007) The receptor of the type I interferon family. Curr. Top. Microbiol. Immunol. 316, 71-95
13. Lavoie, T. B., Kalie, E., Crisafulli-Cabatu, S., Abramovich, R., DiGioia, G., Moolchan, K., Pestka, S., and Schreiber, G. (2011) Binding and activity of all human α interferon subtypes. Cytokine. 56, 282-289
14. AUSTIMS Research Group. (1989) Interferon-α and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. J. Neurol. Neurosurg. Psychiatry. 52, 566-574
15. Heathcote, E. J., Shiffman, M. L., Cooksley, W. G., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., Hoffman, J., and De Pamphilis, J. (2000) Peginterferon alfa-2α in patients with chronic hepatitis C and cirrhosis. N Engl. J. Med. 343, 1673-1680
16. Dhalluin, C., Ross, A., Huber, W., Gerber, P., Brugger, D., Gsell, B., and Senn, H. (2005) Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-α2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug. Chem. 16, 518-527
17. Baker, D. P., Lin, E. Y., Lin, K., Pellegrini, M., Petter, R. C., Chen, L. L., Arduini, R. M., Brickelmaier, M., Wen, D., Hess, D. M., Chen, L., Grant, D., Whitty, A., Gill, A., Lindner, D. J., and Pepinsky, R. B. (2006) N-terminally PEGylated human interferon-β-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug. Chem. 17, 179-188
18. Hu, X., Miller, L., Richman, S., Hitchman, S., Glick, G., Liu, S., Zhu, Y., Crossman, M., Nestorov, I., Gronke, R. S., Baker, D. P., Rogge, M., Subramanyam, M., and Davar, G. (2012) A novel PEGylated interferon β-1a for multiple sclerosis: safety, Pharmacology, and biology. J. Clin. Pharmacol. 52, 798-808
19. Reuss, R. (2013) PEGylated interferon β-1a in the treatment of multiple sclerosis: an update. Biol. Targets Ther. 7, 131-138
20. Calabresi, P. A., Kieseier, B. C, Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., Deykin, A., and ADVANCE Study Investigators (2014) Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 13, 657-665
21. Roisman, L. C, Jaitin, D. A., Baker, D. P., and Schreiber, G. (2005) Mutational analysis of the IFNAR1 binding site on IFNα2 reveals the architecture of a weak ligand-receptor binding-site. J. Mol. Biol. 353, 271-281
22. Kalie, E., Jaitin, D. A., Abramovich, R., and Schreiber, G. (2007) An interferon a2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J. Biol. Chem. 282, 11602-11611
23. Levin, D., Harari, D., and Schreiber, G. (2011) Stochastic receptor expression determines cell fate upon interferon treatment. Mol. Cell. Biol. 31, 3252-3266
24. Harari, D., Abramovich, R., Zozulya, A., Smith, P., Pouly, S., Köster, M., Hauser, H., and Schreiber, G. (2014) Bridging the species divide: transgenic mice humanized for type-I interferon response. PLoS One 9, e84259
25. Schlapschy, M., Binder, U., Börger, C, Theobald, I., Wachinger, K., Kisling, S., Haller, D., and Skerra, A. (2013) PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng. Des. Sel. 26, 489-501
26. Meerman, H. J., and Georgiou, G. (1994) Construction and characterization of a set of E. coli strains deficient in all known loci affecting the proteolytic stability of secreted recombinant proteins. Biotechnology (NY). 12, 1107-1110
27. Schlapschy, M., Grimm, S., and Skerra, A. (2006) A system for concomitant overexpression of four periplasmic folding catalysts to improve secretory protein production in Escherichia coli. Protein Eng. Des. Sel. 19, 385-390
28. Schiweck, W., and Skerra, A. (1995) Fermenter production of an artificial Fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Proteins. 23, 561-565
29. Fernald, G. H., Knott, S., Pachner, A., Caillier, S. J., Narayan, K., Oksenberg, J. R., Mousavi, P., and Baranzini, S. E. (2007) Genome-wide network analysis reveals the global properties of IFN-β immediate transcriptional effects in humans. J. Immunol. 178, 5076-5085
30. Begum, F., Zhu, W., Namaka, M. P., and Frost, E. E. (2010) A novel decalcification method for adult rodent bone for histological analysis of peripheral-central nervous system connections. J. Neurosci. Methods. 187, 59-66
31. Jaitin, D. A., Roisman, L. C, Jaks, E., Gavutis, M., Piehler, J., Van der Heyden, J., Uze, G., and Schreiber, G. (2006) Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol. Cell. Biol. 26, 1888-1897
32. Pulverer, J. E., Rand, U, Lienenklaus, S., Kugel, D., Zietara, N, Kochs, G., Naumann, R., Weiss, S., Staeheli, P., Hauser, H., and Köster, M. (2010) Temporal and spatial resolution of type I and III interferon responses in vivo. J. Virol. 84, 8626-8638
33. Williams, G. J., and Witt, P. L. (1998) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J. Interferon Cytokine Res. 18, 967-975
34. Mahmood, I. (2005) Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling, 1st Ed., Pine House Publishers, Rockville, MD
35. Mendel, I., Kerlero de Rosbo, N, and Ben-Nun, A. (1995) A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V β expression of encephalitogenic T cells. Eur. J. Immunol. 25, 1951-1959
36. Croxford, A. L., Kurschus, F. C, and Waisman, A. (2011) Mouse models for multiple sclerosis: historical facts and future implications. Biochim. Biophys. Acta. 1812, 177-183
37. van der Meide, P. H., de Labie, M. C, Ruuls, S. R., Groenestein, R. J., Botman, C. A., Olsson, T., and Dijkstra, C. D. (1998) Discontinuation of treatment with IFN-β leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats: rapid reversal of the antiproliferative activity of IFN-β and excessive expansion of autoreactive T cells as disease promoting mechanisms. J. Neuroimmunol. 84, 14-23
38. Meyniel, C, Spelman, T., Jokubaitis, V. G., Trojano, M., Izquierdo, G., Grand'Maison, F., Oreja-Guevara, C, Boz, C, Lugaresi, A., Girard, M., Grammond, P., Iuliano, G., Fiol, M., Cabrera-Gomez, J. A., Fernandez-Bolanos, R., Giuliani, G., Lechner-Scott, J., Cristiano, E., Herbert, J., Petkovska-Boskova, T., Bergamaschi, R., van Pesch, V., Moore, F., Vella, N, Slee, M., Santiago, V., Barnett, M., Havrdova, E., Young, C, Sirbu, C.-A., Tanner, M., Rutherford, M., Butzkueven, H., and MSBasis Study Group (2012) Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One 7, e38661
39. Vremec, D., Pooley, J., Hochrein, H., Wu, L., and Shortman, K. (2000) CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164, 2978-2986
40. Esashi, E., Sekiguchi, T., Ito, H., Koyasu, S., and Miyajima, A. (2003) Cutting edge: a possible role for CD4+ thymic macrophages as professional scavengers of apoptotic thymocytes. J. Immunol. 171, 2773-2777
41. Liu, Y., Carlsson, R., Comabella, M., Wang, J., Kosicki, M., Carrion, B., Hasan, M., Wu, X., Montalban, X., Dziegiel, M. H, Sellebjerg, F., Sørensen, P. S., Helin, K., and Issazadeh-Navikas, S. (2014) FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat. Med. 20, 272-282
42. Pachner, A. R., Bertolotto, A., and Deisenhammer, F. (2003) Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology. 61, S24-S26
43. Sellebjerg, F., Datta, P., Larsen, J., Rieneck, K., Alsing, I., Oturai, A., Svejgaard, A., Soelberg Sørensen, P., and Ryder, L. P. (2008) Gene expression analysis of interferon-β treatment in multiple sclerosis. Mult. Scler. 14, 615-621
44. Hesse, D., Sellebjerg, F., and Sorensen, P. S. (2009) Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity. Neurology. 73, 372-377
45. van der Voort, L. F., Vennegoor, A., Visser, A., Knol, D. L., Uitdehaag, B. M., Barkhof, F., Oudejans, C. B., Polman, C. H., and Killestein, J. (2010) Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology. 75, 1228-1233
46. Hundeshagen, A., Hecker, M., Paap, B. K., Angerstein, C, Kandulski, O., Fatum, C, Hartmann, C, Koczan, D., Thiesen, H.-J., and Zettl, U. K. (2012) Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J. Neuroinflammation 9, 140
47. Serana, F., Imberti, L., Amato, M. P., Comi, G., Gasperini, C., Ghezzi, A., Martinelli, V., Provinciali, L., Rottoli, M. R., Sotgiu, S., Stecchi, S., Vecchio, M., Zaffaroni, M., Cordioli, C., and Capra, R. (2014) MxA mRNA quantification and disability progression in interferon β-treated multiple sclerosis patients. PLoS One 9, e94794
48. Sandler, N. G., Bosinger, S. E., Estes, J. D., Zhu, R. T., Tharp, G. K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K. N, del Prete, G. Q., Hill, B. J., Timmer, J. K., Reiss, E., Yarden, G., Darko, S., Contijoch, E., Todd, J. P., Silvestri, G., Nason, M., Norgren, R. B., Jr., Keele, B. F., Rao, S., Langer, J. A., Lifson, J. D., Schreiber, G., and Douek, D. C. (2014) Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 511, 601-605
49. Río, J., Nos, C., Tintoré, M., Téllez, N, Galán, I., Pelayo, R., Comabella, M., and Montalban, X. (2006) Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59, 344-352
50. Baranzini, S. E. (2013) Gene expression profiling in MS: a fulfilled promise? Mult. Scler. 19, 1813-1814
51. Lublin, F. D., and Reingold, S. C. (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (U. S. A.) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 46, 907-911
52. Goldman, M. D., Motl, R. W., and Rudick, R. A. (2010) Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther. Adv. Neurol. Disord. 3, 229-239
53. Lucchinetti, C, Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., and Lassmann, H. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717
54. Karussis, D. (2014) The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J. Autoimmun. 48-49, 134-142
55. Guo, B., Chang, E. Y., and Cheng, G. (2008) The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118, 1680-1690
56. Prinz, M., Schmidt, H., Mildner, A., Knobeloch, K.-P., Hanisch, U.-K., Raasch, J., Merkler, D., Detje, C, Gutcher, I., Mages, J., Lang, R., Martin, R., Gold, R., Becher, B., Brück, W., and Kalinke, U. (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity. 28, 675-686
57. Teige, I., Treschow, A., Teige, A., Mattsson, R., Navikas, V., Leanderson, T., Holmdahl, R., and Issazadeh-Navikas, S. (2003) IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170, 4776-4784
58. Galligan, C. L., Pennell, L. M., Murooka, T. T., Baig, E., Majchrzak-Kita, B., Rahbar, R., and Fish, E. N. (2010) Interferon-β is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult. Scler. 16, 1458-1473
59. Axtell, R. C, de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., De Sarno, P., Naves, R., Han, M., Zhong, F., Castellanos, J. G., Mair, R., Christakos, A., Kolkowitz, I., Katz, L., Killestein, J., Polman, C. H., de Waal Malefyt, R., Steinman, L., and Raman, C (2010) T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med. 16, 406-412